Differential Intervention Trial by Standard Therapy Versus Pitavastatin in Patients With Chronic Hemodialysis (DIALYSIS)
NCT ID: NCT00846118
Last Updated: 2021-08-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
905 participants
INTERVENTIONAL
2009-02-01
2014-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Pitavastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease
NCT02863185
Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin in Coronary Artery Disease (REAL-CAD)
NCT01042730
Atorvastatin Treatment to Attenuate the Progression of Cardiovascular Disease in Hemodialysis Patients
NCT00481364
The Role of Atorvastatin on Monocyte Function in Patients With Coronary Artery Disease and Hypercholesterolemia
NCT00329069
Atorvastatin Effects On Arterial Stiffness In Hemodialysis
NCT04472637
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pitavastatin
Pitavastatin in addition to optimal standard care
Pitavastatin
1-4mg/day
optimal standard care
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pitavastatin
1-4mg/day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients with hypercholesterolemia as defined by any of following parameters:
* LDL-C ≧ 100 mg / dL
* TC ≧ 180 mg / dL
* patients required cholesterol-lowering treatment by investigators.
* patients aged 20-75 years
* patients with written consent by their own volition after being provided sufficient explanation for the participation into this clinical trial
Exclusion Criteria
* patients enrolled to the other trials using contraindication drugs of pitavastatin
* patients who had acute myocardial infarction within six months before the day of the agreement acquisition
* patients scheduled PCI and CABG within six months after the day of the agreement acquisition
* Patients who had diagnosis or doubt of malignant tumor
* patients corresponded to "Contraindications" of pitavastatin
* Familial hypercholesterolemia patients
* patients judged ineligible by investigators
20 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chieko Hamada
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chieko Hamada
Division of Nehprology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yasuhiko Tomino, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
Professor of Medicine, Department of Nephrology, Juntendo University Graduate School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Division of Nephrology, Department of Internal Medicine, Juntendo Hospital
Tokyo, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
208-032
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.